Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ULK1 | O75385 | 3/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983518 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2401641 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14166088 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1543561 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28410100 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1543565 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL18047346 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL10705966 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL2175329 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL14166087 | 0.98 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454532-B2 | Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) | FORMA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250304583-A1 | INHIBITING G CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) | FORMA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12378242-B2 | Inhibiting CREB binding protein (CBP) | FORMA THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-119684285-A | Inhibition of cyclic AMP-responsive element binding proteins (CREB) | 福马治疗股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-113874017-B | Inhibition of cyclic AMP-responsive element binding proteins (CREB) | 福马治疗股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113784967-B | Compositions and methods for treating androgen receptor positive forms of cancer | 福马治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240150347-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) | FORMA THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-9962375-B2 | Methyl-piperidine compounds useful for inhibiting microsomal prostaglandin E2 synthase-1 | ELI LILLY AND COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | ELI LILLY AND COMPANY | 2017-11-16 | — | — | US | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304583-A1 | INHIBITING G CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) | CREBBP, CREB1, EP300 | SMN1; SMN2 3198/4885CHRNB2 1937/4885CHRNA4 2226/4885 |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | SMN1; SMN2 2779/4885CHRNB2 3357/4885CHRNA4 3572/4885 |
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | PTGS1, PTGES, PTGER1 | SMN1; SMN2 2563/4885CHRNB2 3742/4885CHRNA4 3195/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | SMN1; SMN2 2779/4885CHRNB2 3357/4885CHRNA4 3572/4885 |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | SMN1; SMN2 2738/4885CHRNB2 850/4885CHRNA4 763/4885 |
| US-12378242-B2 | Inhibiting CREB binding protein (CBP) | CREBBP, EP300, CREB1 | SMN1; SMN2 2092/4885CHRNB2 914/4885CHRNA4 1296/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | SMN1; SMN2 2779/4885CHRNB2 3357/4885CHRNA4 3572/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | SMN1; SMN2 1659/4885CHRNB2 836/4885CHRNA4 600/4885 |
| US-12454532-B2 | Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) | CREBBP, CREB1, EP300 | SMN1; SMN2 2799/4885CHRNB2 1773/4885CHRNA4 2239/4885 |
| US-20240150347-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) | CREBBP, CREB1, EP300 | SMN1; SMN2 2799/4885CHRNB2 1773/4885CHRNA4 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.